Summary of Key Information:

Reporting Period (Quarter/Year): Not Specified

Nature of Filing / Announcement: Outcome of Board Meeting held on June 4, 2026

Audit Opinion:

Not Specified

Key Financial Highlights:

Not Specified

Standalone Results:

Not Specified

Consolidated Results:

Not Specified

Segment-wise Performance:

Not Specified

Corporate Actions:

  • Approved preferential issuance of 1,32,56,470 (One Crore Thirty Two Lakh Fifty Six Thousand Four Hundred and Seventy) fully paid-up Equity Shares at a price of ₹347/- per share (including a premium of ₹337/- each)
  • Total issue size: ₹459,99,95,090 (Four Hundred Fifty Nine Crore Ninety Nine Lakh Ninety Five Thousand Ninety Only)
  • Shares to be issued to non-promoters as determined under SEBI (ICDR) Regulations, 2018
  • Approved appointment of India Ratings and Research Private Limited as the Monitoring Agency under Regulation 162A of SEBI ICDR Regulations
  • Approved issue of 4,32,777 (Four Lakhs Thirty Two Thousand Seven Hundred and Seventy Seven) Equity Shares of ₹10/- each on preferential basis for consideration other than cash
  • The share swap is for acquiring additional 25% equity shareholding in subsidiary AS Strategic Private Limited
  • Approved draft Notice for convening Extra-ordinary General Meeting (EGM) on June 28, 2026 through Video Conferencing/Other Audio-Visual Means

Other Significant Information:

Preferential Issue Allottees (Annexure I(A)):

The preferential issue includes 32 allottees, all non-promoters, including:

  • Mutual Funds: Bank of India Flexi Cap Fund (734,870 shares), Bank of India Small Cap Fund (680,115 shares), Taurus Flexi Cap Fund (345,821 shares), and others
  • Corporate Entities: Akshat Greentech Private Limited (1,440,922 shares), Rudira Aqua Limited (432,276 shares), Citron Realty LLP (432,276 shares), A.P.T.Research Private Limited (432,276 shares), VLS Generics And Biosimilars Private Limited (288,184 shares)
  • Individuals: Bhaskara Rao Bollineni (1,440,922 shares), Amritha Vellodi (1,440,922 shares), Kuldip Singh Rathee (720,461 shares), and others
  • Total pre-issue shareholding of allottees: 8,22,500 shares (0.05%)
  • Post-issue shareholding of allottees: 1,40,78,970 shares (7.41%)

Subsidiary Acquisition Details (Annexure II & II(A)):

  • Target Entity: AS Strategic Private Limited (subsidiary)
  • Current holding: 51% equity shareholding
  • Additional acquisition: 25% equity shareholding
  • Post-acquisition holding: 76% equity shareholding
  • Acquisition method: Share swap (4,32,777 equity shares of Sigma Advanced Systems)
  • Industry: Aerospace & Defence
  • Turnover (12 months ended March 2025): ₹608 lacs
  • Strategic rationale: Strengthening and expanding the Company's defence business globally by creating an integrated and scalable platform
  • Not a related party transaction - promoter/promoter group/group companies have no interest in the entity
  • Timeframe for completion: Within 6 to 8 weeks
  • Approximate cost of acquisition: ₹15 Crores (discharged through share swap)
  • Company background: Defence and Aerospace focused company based at Delhi working through long-term joint ventures and partnerships with leading European and global defence OEMs

Advisors for Preferential Issue:

  • InCred Capital Wealth Portfolio Managers Private Limited
  • Spark PWM Private Limited (Spark Capital)